Gur Roshwalb
Director/Board Member at MiNA Therapeutics Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ivor Royston | M | 79 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | - |
Barry Simon | M | 59 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 7 years |
Nagy Habib | M | 72 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | 16 years |
Judy Chou | M | 58 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | - |
Raymond Prudo-Chlebosz | M | 79 | 9 years | |
Osman Kibar | M | - |
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | 16 years |
Roger Pomerantz | M | 67 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 4 years |
Aron M. Knickerbocker | M | 54 |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | 4 years |
Ashleigh Barreto | F | - | 3 years | |
Yair Schindel | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 8 years |
Tomer Berkovitz | M | 44 |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 6 years |
Jane Barlow | M | 63 | 3 years | |
Thomas Darcy | M | 74 | 3 years | |
Peter Bains | M | 66 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | - |
Robert Lechler | M | - |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | 2 years |
Reut Shema | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 6 years |
Susan Clement Davies | F | 62 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | 2 years |
Stephen Rubino | M | 65 | 3 years | |
Robert Sebastian Habib | M | 39 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | - |
Alon Altschuler | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 6 years |
Tamar Farfel-Becker | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 5 years |
Yodfat Melzer | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 4 years |
Donald Williams | M | 65 | 8 years | |
Flavia Borellini | M | 65 | 3 years | |
Jim Woody | M | 81 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | - |
Marius Nacht | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 8 years |
Cevdet Samikoglu | M | - |
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | - |
Finian Tan | M | - |
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | - |
Ohad Hollander | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 3 years |
Sam Murphy | M | 47 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 5 years |
Jennifer Minai-Azary | F | 46 |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | 2 years |
Avital Adler | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 4 years |
Uri Kedem | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 3 years |
Raluca Ragab | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 2 years |
Ayman El-Guindy | M | - | 3 years | |
Patric Nelson | M | - | 3 years | |
Biljana Nadjsombati | F | - | 3 years | |
Yael Gruenbaum-Cohen | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 2 years |
Yaniv Sadka | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 3 years |
Osnat Tirosh | M | 55 |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 1 years |
Patrick Yang | M | 75 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | - |
Lloyd Minor | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | - |
Steve Burnell | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | - |
Daniel A Ginsburg | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 4 years |
Noam Waldoks | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 4 years |
Elinor Belkine Michaeli | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 6 years |
Alexis Bolner | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 4 years |
Yonina Berman | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 3 years |
Noah Lasson | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 2 years |
Yael Tzach | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 4 years |
Maya Epstein | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 3 years |
Maya Tollman Toledano | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 2 years |
Richard Ghalie | M | 66 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 9 years |
Chaim Martin | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 2 years |
Brachie Sprung | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 5 years |
Tamir Maixner | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 7 years |
Robert Langer | M | 74 |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | - |
Stephen G. Juelsgaard | M | 75 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | - |
Merav Kaye | F | 51 |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | - |
Troy Cox | M | 60 |
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | - |
Thomas Bengt Eldered | M | 64 |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | - |
Kyle Rasbach | M | - |
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | - |
Yaron Daniely | M | 48 |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 5 years |
Corazon Sanders | M | 67 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | 4 years |
Stewart M. Brown | M | - | 2 years | |
Carl-Johan Spak | M | 68 |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | 7 years |
Sean Bohen | M | 57 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | 5 years |
Robert Kopple | M | 81 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | - |
Daniel Chevallard | M | 44 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 5 years |
Anat Bar-Gera | F | 66 |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 3 years |
Roy Wiesner | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 6 years |
Tamar Raz | M | 61 |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | 10 years |
Michel Moise Habib | M | 57 |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | 8 years |
Todd Sone | M | 53 |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 7 years |
Miles Nunn | M | - | 9 years | |
Irena Katsman | F | 44 |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 6 years |
Eyal Lifschitz | M | - |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | - |
Yaron Pereg | M | - |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | 7 years |
Isaac Devash | M | 62 |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | - |
Kieran Johnson | M | 55 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | - |
Vered Gigi | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 2 years |
Susannah Gray | F | 63 |
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | - |
John C. Doyle | M | 55 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | - |
Daniel Cohen | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | - |
Christopher Barry Wood | M | 78 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | - |
Michael Huang | M | 50 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 5 years |
Moshe Mor | M | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 4 years |
Emily Rosuck | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Clive Richardson | M | 60 | - | |
Allan Shaw | M | 59 | 3 years | |
Robert M. Shaw | M | 70 | 2 years | |
Nicole Onetto | M | 71 | 2 years | |
James Hill | M | 78 | 8 years | |
David Byrne | M | 64 | 7 years | |
Robert E. Ward | M | 66 | 2 years | |
Mark S. Cohen | M | 56 | - | |
Stuart Ungar | M | 80 | - | |
Kobi Vinokur | M | 47 |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | - |
Michal Goren Miller | F | - |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | 5 years |
Bryan Jennings | M | - |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
Israel | 51 | 51.00% |
United States | 41 | 41.00% |
United Kingdom | 8 | 8.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gur Roshwalb
- Personal Network